VEGF_{165} Gene Therapy Improves Left Ventricular Function and Exercise Capacity in Diabetic Rats after Myocardial Infarction: Impact on Mortality Rate

Bruno Rodrigues1,2, Cristiano T. Mostarda3, Kaleizu T. Rosa3, Melissa Markoski2, Nance B. Nardi4, Kátia De Angelis5, Maria Cláudia Irigoyen2 and Renato A. K. Kalil5

Abstract

Despite the increased amount of evidence about the benefits of human vascular endothelial growth factors by plasmid (pHuVEGF_{165}) based gene transfer after an ischemic event, the effects of pHuVEGF_{165} therapy in diabetic hearts after myocardial infarction (MI) remains poorly investigated. We evaluated the effects of intramyocardial pHuVEGF_{165} injection on left ventricular (LV) morphometry, function and blood flow, maximal oxygen consumption (VO_{2max}), and the total mortality rate of diabetic rats after MI. Male Wistar rats were divided into control (C), myocardial infarction+saline injection (I+SAL), myocardial infarction+pHuVEGF_{165} injection (I+VEGF), diabetes+myocardial infarction+saline injection (DI+SAL), and diabetes+myocardial infarction+pHuVEGF_{165} injection (DI+VEGF). MI was induced after 15 days of streptozotocin diabetes induction. One day after MI, the animals received pHuVEGF_{165} or saline intramyocardial injection. LV function and maximal oxygen consumption (VO_{2max}) were evaluated at the initial injection and 30 days after injections. MI area evaluation showed an additional reduction in DI+VEGF (8±1%) in comparison with group I+VEGF (31±3%). Improvement in systolic function, evaluated invasively and noninvasively, lung wet/dry weight ratio, and VO_{2max} were observed in both pHuVEGF_{165} injected groups. Consequently, mortality rate was reduced in I+VEGF (19%) and DI+VEGF (12.5%) when compared with I+SAL (48%) and DI+SAL (37.5%) groups. In conclusion, pHuVEGF_{165} therapy resulted in reduced MI area, stabilization and maintenance of left ventricular function, increased VO_{2max}, and reduced mortality in MI animals, diabetic or not. These results highlight the importance of continuing experimental studies and controlled clinical trials of gene therapy for ischemic cardiomyopathy associated with the pathological conditions of diabetes.

Keywords: Diabetes; Myocardial infarction; pHuVEGF_{165} injection; LV function; VO_{2max}; Mortality

Introduction

The diabetes in developed countries is approaching epidemic proportions and has been associated with an increased risk of cardiovascular abnormalities and death from cardiovascular causes [1]. More specifically, diabetes mellitus increases the frequency and severity of myocardial infarction (MI) in persons with diabetes [2,3] compared with age-matched persons without diabetes. Furthermore, these individuals have a 2- to 3-fold greater risk of developing congestive heart failure after MI and suffer from increased mortality after acute MI [4].

Although clinical studies have clearly established a correlation between diabetes mellitus and increased severity of MI, very little is currently known regarding the pathophysiological mechanisms involved in the response of the diabetic heart to ischemic injury. In the experimental setting, our group has evidenced that diabetic rats have an imbalance in the oxidative stress profile [5], changes in the cellular survival pathway [6], reduced expression of the cardiac calcium handling proteins and ventricular function [7] at different times after MI.

Gene transfer constitutes an alternative strategy for accomplishing therapeutic angiogenesis in patients with limb and myocardial ischemia. Transient myocardial overexpression of human vascular endothelial growth factors A (huVEGF) by adenovirus or plasmid (pHuVEGF) based gene transfer induces angiogenesis both experimentally and in patients with myocardial ischemia [8]. In fact, small and unblinded gene therapy studies of intramyocardial delivered genes encoding VEGF-A_{165} or VEGF-A_{121}, have been performed in patients with severe coronary artery diseases, and results have been encouraging, demonstrating both clinical improvement and evidence of angiogenesis [9,10]. However, despite the catastrophic complications of MI in those with diabetes, the effects of pHuVEGF_{165} therapy associated with these 2 pathological conditions have been poorly investigated. This study was undertaken to test the hypothesis that intramyocardial pHuVEGF_{165} injection in diabetic rats undergoing MI improves left ventricular (LV) dysfunction and maximal exercise capacity, and consequently this positive adaptation could impact survival. The present investigation was designed to evaluate the effects of intramyocardial pHuVEGF_{165} injection on (i) LV morphometry and function; (ii) maximal oxygen consumption (VO_{2max}); and (iii) total mortality rate of diabetic rats after MI.

*Corresponding author: Bruno Rodrigues, PhD, Hypertension Unit, Heart Institute (InCor), Medical School of University of São Paulo, São Paulo, Brazil. E-mail: bruno.rodrigues@incc.usp.br

Received November 24, 2011; Accepted December 18, 2011; Published December 22, 2011

Citation: Rodrigues B, Mostarda CT, Rosa KT, Markoski M, Nardi NB, et al. (2011) VEGF_{165} Gene Therapy Improves Left Ventricular Function and Exercise Capacity in Diabetic Rats after Myocardial Infarction: Impact on Mortality Rate. J Diabetes Metab 5: S4-006. doi:10.4172/2155-6156.S4-006

Copyright: © 2011 Rodrigues B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Methods

Production of pHuVEGF<sub>165</sub>

The human vascular endothelial growth factor plasmid (pHuVEGF<sub>165</sub>), a transient and nonviral vector that expresses the VEGF<sub>165</sub> gene transcriptionally regulated by the cytomegalovirus promoter/enhancer, was obtained from Genentech (San Francisco, CA, USA) and introduced into XL1-Blue Escherichia coli by standard heat-shock transformation. Three clones of transformed cells were analyzed with different restriction enzymes, and one of them was selected for further cloning. The resulting plasmid was extracted with the PureLink<sup>TM</sup> HiPure Plasmid Maxiprep Kit (Invitrogen, USA), which allows the isolation of a large amount of DNA (0.5-1 mg). Plasmid integrity was analyzed by electrophoresis in agarose gel stained with ethidium bromide, and DNA was quantified by spectrophotometry at 260-280 nm [11,12].

Experimental design

Experiments were performed in adult male Wistar rats (~290g) from the Animal House of the University of São Paulo, São Paulo, Brazil. Rats were fed standard laboratory chow and water ad libitum. The animals were housed in collective polycarbonate cages in a temperature-controlled room (22°C) with a 12-hour dark-light cycle (light 07:00-19:00h). The experimental protocol was approved by the institutional animal care and use committee of the Medical School of the University of São Paulo, and this investigation was conducted in accordance with previously described [13]. Fifty days after diabetes induction or buffer injection, the animals underwent surgical occlusion of the left coronary artery, which resulted in MI. One day after MI surgery, echocardiographic analyses were used to measure the MI area and the ejection fraction (EF). Only animals with EF<55% and MI area>30% were kept in the experiment (30% were excluded). The rats received either pHuVEGF<sub>165</sub> or saline intramyocardial injection. Maximal oxygen consumption (VO<sub>max</sub>) was measured one day after the injections (two days after MI), and the animals were followed for 30 days. After this period, echocardiographic and VO<sub>max</sub> evaluations, as well as invasive left ventricular function and blood flow measurements were realized, as observed in (Figure 1). Rats were randomly assigned to control (C, n=16), myocardial infarction + saline injection (I+SAL, n=16), myocardial infarction + pHuVEGF<sub>165</sub> injection (I+VEGF, n=16), diabetes + myocardial infarction + saline injection (DI+SAL, n=16) and diabetes + myocardial infarction + pHuVEGF<sub>165</sub> injection (DI+VEGF, n=16). The whole sample (n=80) was evaluated for mortality, an assessment that was started after pHuVEGF<sub>165</sub> or saline intramyocardial injection, excluding the influence of anesthesia or stress from the surgical procedure. Additional evaluations were performed in 8 other animals from each group.

Diabetes induction

Experimental diabetes was induced by intravenous injection of 50 mg/kg STZ (Sigma Chemical Co., St. Louis, MO) dissolved in citrate buffer (pH 4.2). Rats were fasted overnight before STZ injection. Control rats were injected with buffer only (10 mM citrate buffer, pH 4.5). Forty-eight hours after STZ injection, diabetes was confirmed by blood glucose levels above 200 mg/dL [7].

Myocardial infarction

Fifteen days after diabetes induction or buffer injection, anesthetized rats (80mg/kg ketamine and 12mg/kg Xylazine, i.p.) underwent surgical occlusion of the left coronary artery or sham, which resulted in myocardial infarction, as previously described elsewhere [5,7,14]. Briefly, a left intercostal thoracotomy was performed, the third intercostal space dissected, and the heart exposed. The left anterior descending coronary artery was occluded with a single nylon (6.0) suture at approximately 1 mm distal to the left atrial appendage. The sham rats (C group) underwent the same procedures except that myocardial ischemia was not induced. The chest was closed with silk suture. The animals were maintained in the ventilator until recovery. All rats received antibiotics (penicillin, 20,000 U) and Tramadol (20 mg/kg, every 6 h).

Intramyocardial injection

A left intercostal thoracotomy was newly performed in the third intercostal space, and the heart exposed. In the VEGF groups (I+VEGF and DI+VEGF), the rats received 50 μg of plasmid dissolved in 75 μl saline. A suture was made in the middle area of the MI to make a landmark for the injection. Plasmid was injected intramyocardially with an insulin syringe (0.3 mm in diameter) at 5 locations into the peri-infarction region along the border of the MI at the level of the suture. Aspiration without retrograde blood filling of the syringe was used as a sign that the needle was in the myocardium but not in the left ventricular cavity [11,12].

Noninvasive evaluation of left ventricular function: echocardiographic measurements

Echocardiography was performed by a double-blinded observer, under the guidelines of the American Society of Echocardiography, 1 day (initial evaluation) after MI and 30 days (final evaluation) after pHuVEGF<sub>165</sub> or saline intramyocardial injection. Rats were anesthetized (80 mg/kg ketamine and 12 mg/kg xylazine), and images were obtained with a 10-14 MHz linear transducer in a SEQUOIA 512 (ACUSON Corporation, Mountain View, CA) for measurement of morphometric parameters: left ventricular (LV) mass (corrected by body weight) and LV end-diastolic diameter (LVEDD); systolic function parameters: ejection fraction (EF) and velocity of circumferential fiber shortening (VCF); diastolic function parameters: LV isovolumetric relaxation time (IVRT), and peak E deceleration time (EDT) corrected by

![Figure 1: Experimental design.](image_url)
the square root of the R-R interval, because EDT and IVRT are HR dependent; and global function: myocardial performance index (MPI). Echocardiographic parameters were measured as described in detail elsewhere [5,7,14].

Myocardial infarction area determinations

The MI area was evaluated by echocardiography 1 day (initial evaluation) after MI and 30 days (final evaluation) after pHuVEGF or saline intramyocardial injection. The infarction area was delimited taking into account the movement of LV walls, by the observation of longitudinal, apical, and transversal views of the LV. Regions with systolic thickness under normal, as well as portions with paradoxical movement, were considered as infarcted. The infarcted area (%) was thus determined by the ratio of these regions by the total area of LV walls [5,7,14]. To confirm the echocardiography, the MI area was also analyzed after all other evaluations (30 days after pHuVEGF or saline injections) by dissecting the fibrous scar from the remaining LV muscle. The outlines of both fragments were drawn on graph paper, and their areas were measured by the cross-point method [15]. The interventricular septum was considered part of the left ventricle.

Maximal oxygen consumption (VO₂ max)

VO₂ max was measured at 2 and 31 days after pHuVEGF or saline intramyocardial injection. The VO₂ max was determined by analysing expired gas during a progressive exercise ramp protocol, with 3 m/minute increments every 3 minutes and no grade until exhaustion. Gas analysis was performed using an oxygen (S-3A/I) analyzer (Ametek, Pittsburgh, PA, USA). The VO₂ was calculated using the measured flow through the metabolic chamber, the expired fraction of effluent oxygen, and the fraction of oxygen in room air, as described elsewhere [14,16].

Left ventricular catheterization and microspheres infusion

LV function was also measured invasively in anesthetized rats (pentobarbital sodium, 40 mg/kg) one day after the VO₂ max evaluation. One catheter of PE-50 was inserted into the right carotid artery and advanced into the LV. Ventricular pressure signals were measured with a transducer and conditioner (Blood Pressure XDCR, Kent Scientific, USA) and digitally recorded (5 min) with a data acquisition system (WinDaq, 2-kHz, DATAQ, Springfield, OH). The recorded data were analyzed on a beat-to-beat basis to quantify changes in LV pressure. The following indices were obtained: heart rate (HR), LV systolic pressure (LVSP), LV end-diastolic pressure (LVEDP), and maximum rate of LV pressure rise and fall (+dP/dt and -dP/dt), as previously described [7,14]. After LV pressure basal records, yellow (150,000) 15 mm Dye-Trak microspheres (Triton Technology, San Diego, CA, USA) were infused to evaluate blood flow measurements in the LV. Microspheres infusion and processing were performed as described previously [14].

Statistical analysis

Data are reported as means ± SEM. After confirming that all continuous variables were normally distributed using the Kolmogorov-Smirnov test, statistical differences between the groups were obtained by two-way and repeated measures ANOVA followed by the Student-Newman-Keuls post-test. Pearson’s correlation was used to study the association between different parameters. The survival curve was estimated by the Kaplan-Meier method and compared by the Log-rank (Mantel-Cox) Test. All tests were two-sided, and the significance level was established at p<0.05. Statistical calculations were performed using SPSS version 12.0.

Results

Animals

At the beginning of the protocol, body weight was similar between the groups (~290 ±15g). After 30 days of pHuVEGF or saline injection, STZ-diabetic rats had a reduced body weight (DI+SAL: 232 ± 7 and DI+VEGF: 294 ± 12g) compared with nondiabetic rats (I+VEGF: 349 ± 9 and I+VEGF: 415 ± 12g). Furthermore, the groups that were injected with VEGF (I+VEGF and DI+VEGF) displayed increased body weight compared with their respective saline injected groups (I+SAL and DI+SAL). Glycemia was increased in STZ-diabetic rats (DI+SAL: 400 ± 27 and DI+VEGF: 371 ± 37 mg/dL) in comparison with nondiabetic rats (I+SAL: 90 ± 3 and I+VEGF: 96 ± 3 mg/dL).

Myocardial infarction area and lung wet/dry weight ratio

The MI akinetic area (MI area), measured by echocardiography, was similar between infarcted groups at the beginning of the protocol (Table 1). However, after 30 days of pHuVEGF injection, I+VEGF and DI+VEGF had MI area reduction in comparison with saline injected animals (I+SAL and DI+SAL). In addition, DI+SAL and DI+VEGF had a reduction of MI area compared with that in I+SAL and I+VEGF groups, respectively. Parallel to this procedure, we also evaluated the MI area by millimeter graph paper stamps (MGPS). Corroborating the final echocardiographic data, I+VEGF and DI+VEGF had reduced MI area in comparison with saline injected animals (I+SAL and DI+SAL) and displayed a positive correlation (r =0.9, p<0.0001) between these two MI area measurements.

The lung wet/dry weight ratio was increased in all experimental groups in relation to that in the C group (Table 1). DI+SAL had an additional increase in comparison with I+SAL. However, I+VEGF and DI+VEGF animals displayed reduced lung wet/dry weight ratio compared with their respective saline injected groups. Furthermore, it is important to highlight that DI+VEGF had an additional reduction in relation to I+VEGF group, as observed in (Table 1).

Maximal oxygen consumption (VO₂ max)

VO₂ max data are presented in (Figure 2). At the initial evaluation, all experimental rats had a reduction in VO₂ max compared with the C group. Nevertheless, at the final evaluation, I+VEGF and DI+VEGF evidenced an increase in VO₂ max in comparison with respective saline injected controls (I+SAL and DI+SAL), and were not different from that in the C animals.

| Parameters | C | I+SAL | I+VEGF | DI+SAL | DI+VEGF |
|------------|---|-------|--------|--------|---------|
| MI area by Echocardiogram | | | | | |
| Initial (%) | 40±2 | 39±2 | 39±2 | 40±1 |
| Final (%) | 31±3 | 31±2 | 32±2 | 30±1 |
| MI area by MGPS | | | | | |
| Final (%) | 46±5 | 34±2 | 35±1 | 12±2 | 3%

Lung Wet/Dry Weight Ratio

| | | | | | |
|---|---|---|---|---|
| | 1.7±0.1 | 5±0.5 | 4±0.5 | 3±0.5 |
| | 1.7±0.4 | 4±0.5 | 3±0.5 | 3±0.5 |
| Values are expressed as mean ± SEM. MGPS = millimeter graph paper stamps. | |

Table 1: Myocardial infarction area determinations and lung wet/dry weight ratio in control (C), myocardial infarction + saline (I+SAL), myocardial infarction + VEGF (I+VEGF), diabetes + myocardial infarction + saline (DI+SAL), and diabetes + myocardial infarction + VEGF (DI+VEGF) groups.
Left ventricular function: noninvasive and invasive evaluations

The noninvasive left ventricular function parameters are shown in Table 2. Initial evaluation, performed 1 day after the MI surgery, showed that LV mass was not different between the groups; however, I+SAL and DI+SAL animals had an increase in this parameter compared with their initial evaluation. LVEDD was increased in I+SAL, I+VEGF, and DI+SAL compared to that in the C group; however, DI+VEGF group was not different than that in the C group. Moreover, diastolic dysfunction was present in I+SAL, I+VEGF, DI+SAL, and DI+VEGF groups compared with C rats, as evidenced by IVRT. All experimental groups displayed reduced systolic function evaluated by EF and VCF in relation to the C group. However, pHuVEGF injected groups (I+VEGF and DI+VEGF) had attenuation of EF in relation to the respective saline injected controls. Additionally, EF was increased in the DI+SAL group in comparison with the I+SAL, and MPI was increased in the I+SAL group compared with the C group, indicating impairment in the global ventricular function in these animals (Table 2).

Invasive LV function data, performed after the final echocardiographic evaluation and shown in Table 3, demonstrated that the LVSP was reduced in all experimental groups compared with that in the C group. Furthermore, STZ-diabetic animals (DI+SAL and DI+VEGF) had additional impairment in LVSP compared with nondiabetic animals. LVEDP was markedly increased in both I+SAL and DI+SAL rats compared with C rats. However, the I+VEGF group had attenuated LVEDP compared with the I+SAL group. HR was reduced in diabetic groups (DI+SAL and DI+VEGF) compared to that in the C and I+SAL groups.

Table 2: Initial and final echocardiographic measurements in control (C), myocardial infarction + saline (I+SAL), myocardial infarction + VEGF (I+VEGF), diabetes + myocardial infarction + saline (DI+SAL), and diabetes + myocardial infarction + VEGF (DI+VEGF) groups.

| Parameters          | C               | I+SAL          | I+VEGF         | DI+SAL         | DI+VEGF        |
|---------------------|-----------------|----------------|----------------|----------------|----------------|
| Morphometric        |                 |                |                |                |                |
| LV mass (g/kg)      | Initial         | 1.02±0.02      | 1.06±0.01      | 1.05±0.04      | 1.04±0.01      | 1.05±0.05      |
|                     | Final           | 1.06±0.03      | 1.15±0.02#     | 1.09±0.01      | 1.14±0.03#     | 1.09±0.04      |
| LVEDD (cm)          | Initial         | 0.65±0.01      | 0.75±0.01*     | 0.76±0.02*     | 0.77±0.03*     | 0.76±0.01*     |
|                     | Final           | 0.67±0.03      | 0.90±0.029#    | 0.79±0.02*     | 0.88±0.03*#†   | 0.74±0.02      |
| Systolic            |                 |                |                |                |                |                |
| EF (%)              | Initial         | 74±2*          | 48±3*          | 47±2*          | 51±3*          | 52±3*          |
|                     | Final           | 71±1*          | 31±2*          | 53±3*†         | 44±3*†         | 53±2*†         |
| VCF (circ/s) (10⁴) | Initial         | 56±3           | 38±2*          | 37±3*          | 38±3*          | 39±1*          |
|                     | Final           | 53±4           | 30±38*         | 39±3*          | 29±29*         | 38±3*          |
| Diastolic           |                 |                |                |                |                |                |
| IVRT (ms)           | Initial         | 1.81±0.07      | 1.81±0.09      | 1.79±0.08      | 1.94±0.08      | 1.90±0.09      |
|                     | Final           | 1.77±0.05      | 2.00±0.07*     | 1.95±0.05      | 2.10±0.03*     | 1.93±0.05*     |
| EDT (ms)            | Initial         | 1.87±0.11      | 1.97±0.10      | 1.99±0.12      | 1.83±0.09      | 1.81±0.07      |
|                     | Final           | 1.81±0.15      | 2.05±0.15      | 2.02±0.10      | 2.10±0.07#     | 2.01±0.04#     |
| Global Function     |                 |                |                |                |                |                |
| MPI                 | Initial         | 0.39±0.01      | 0.46±0.03      | 0.45±0.01      | 0.44±0.03      | 0.45±0.01      |
|                     | Final           | 0.43±0.02      | 0.55±0.028*    | 0.47±0.02†     | 0.48±0.01†     | 0.42±0.02      |

Values are expressed as mean ± SEM. LV mass – Left ventricular mass corrected by body weight; LVEDD – Left ventricular end-diameter during diastole; EF – Ejection fraction; VCF - Velocity of circumferential fiber shortening; EDT- Peak E deceleration time; IVRT- Left ventricular isovolumetric relaxation time; MPI - Myocardial performance index. *p<0.05 vs. initial evaluation; † p<0.05 vs. C; ‡ p<0.05 vs. I+SAL; † p<0.05 vs. DI+SAL (n=8 for each group).

Table 3: Invasive left ventricular function in control (C), myocardial infarction + saline (I+SAL), myocardial infarction + VEGF (I+VEGF), diabetes + myocardial infarction + saline (DI+SAL), and diabetes + myocardial infarction + VEGF (DI+VEGF) groups.

| Parameters          | C               | I+SAL          | I+VEGF         | DI+SAL         | DI+VEGF        |
|---------------------|-----------------|----------------|----------------|----------------|----------------|
| LVSP (mm Hg)        | Initial         | 134±5          | 113±4*         | 120±6*         | 93±4*†         | 94±4*†         |
| LVEDP (mm Hg)       | 5.0±0.3         | 19±2.1*        | 10±0.6†        | 14±3.2*        | 10±0.8        |
| HR (bpm)            | 352±12          | 34±26          | 350±9          | 305±5*†        | 307±10*        |
| +dP/dt (mm Hg/sec)  | 844±1 430       | 464±2 457*     | 690±03×01      | 470±2 325*     | 720±2 621*     |
| -dP/dt (mm Hg/sec)  | -718±1 60      | -321±8 471*    | -532±7 476*    | -352±3 260*    | 520±2 245*     |

Values are expressed as mean ± SEM. LVSP – left ventricle systolic pressure; LVEDP – left ventricle end-diastolic pressure; HR – heart rate; +dP/dt and -dP/dt - maximum rate of LV pressure rise and fall. *p<0.05 vs. C; † p<0.05 vs. I+SAL; ‡ p<0.05 vs. DI+SAL; † p<0.05 vs. I+VEGF; (n=8 for each group).
Left ventricle blood flow

As observed in Figure 3, myocardial infarction reduced left ventricle blood flow in I+SAL and DI+SAL when compared with the C animals. However, pHuVEGF injected groups (I+VEGF and DI+VEGF) displayed an increase of left ventricle blood flow if compared with the saline injected groups.

Mortality rate

Total mortality rate evaluation (Kaplan-Meier survival curve) showed that I+SAL (7 deaths among 16 animals, 43.8% mortality), I+VEGF (3 deaths among 16 animals, 18.8% mortality), DI+SAL (6 deaths among 16 animals, 37.5% mortality) and DI+VEGF (2 deaths among 16 animals, 12.5% mortality) groups had higher mortality rates compared with C (no deaths). However, VEGF-injected animals had an increased survival rate compared with saline-injected controls, as observed in Figure 4.

Discussion

The main findings of the present study are i) MI area was reduced after 30 days of pHuVEGF intramyocardial injection in nondiabetic and STZ-diabetic animals, being associated with improvement of LV blood flow; however, STZ-diabetic animals had an additional reduction in MI area and LV remodeling in comparison with nondiabetic animals; ii) LV function was improved in both I+VEGF and DI+VEGF animals, evaluated noninvasively and invasively; iii) maximal oxygen consumption was increased in pHuVEGF injected rats, assuming values similar to that in the controls. Moreover, it is possible that these positive adaptations have had an influence in the reduced mortality rate observed in the pHuVEGF injected groups.

Myocardial infarction area and LV remodeling

In the present study, MI area was reduced in STZ-diabetic and nondiabetic infarcted animals after 30 days of pHuVEGF intramyocardial injection. In addition, as a reflex of MI area reduction, the lung wet/dry weight ratio, an important index of pulmonary congestion, was also reduced in injected animals. Since the study of Yanagisawa-Miwa et al. [17] where the authors demonstrated in a canine experimental MI model that the intracoronary injection of basic fibroblast growth factor improved cardiac systolic function and reduced infarct size, the effects of angiogenic growth factor injection on MI has been reported. Later, VEGF injection was shown to increase myocardial blood flow in porcine hearts [18]; thus growth factors have been proposed as potential tools for infarct size reduction and blood flow improvement [19]. In this sense, Samuel et al. [20] demonstrated that the combination of gene therapy coexpressing VEGF and angiopoietin-1 significantly reduced the ventricular remodeling, evidenced by the significant reduction in the collagenous fibrotic tissue, in diabetic and nondiabetic infarcted animals. The authors documented that the reduction in the fibrotic tissue may have occurred by the angiogenesis and vessel maturation induction in the treated rats.

A variety of studies have investigated the effects of VEGF to induce angiogenesis. This fact may be a possible explication to the MI area reduction in our study, as well as the LV remodeling frequently observed after MI, that was blunted by the pHuVEGF intramyocardial injection. In this sense, we also observed that LV blood flow was increased in VEGF injected animals evaluated by colored microspheres infusion. It has been previously reported in a canine model of ischemic cardiomyopathy, with myocardial perfusion analysis through scintillography, in which the gene encoding the green
fluorescent protein was successfully transfected [21]. With a similar model, myocardial angiogenesis was induced by transmural injection of plasmoidal VEGF165 in MI areas of dogs [22].

Studies in experimental models of myocardial ischemia involving medium-size mammals have shown that VEGF is arteriogenic, supporting their use in promoting arteriole growth in severe coronary disease [23]. Other roles have also been suggested for VEGF, such as the ability to induce cardiomyocyte cytokinesis, as revealed by cardiomyocyte hyperplasia in an experimental model for ischemia [24]. Furthermore, in the present work, we observed an additional reduction in MI area in diabetic animals compared to nondiabetic animals, treated with pHuVEGF165 or not. The data for MI area in the noninjected animals corroborates previous findings of our group where diabetic animals had reduced heart fibrosis and reduced infarct size [6,7] after 7 and 30 days of MI. In accordance with Malitanto et al. [6], it is possible that the improvement in MI area may have been the final pathway promoted by a positive balance in regulatory genes related to programmed cell survival, reduced inflammatory cytokines, and increased utilization of glucose as an energy substrate.

The favorable results obtained in experimental studies, and the absence of adverse effects related to the use of pHuVEGF165 in initial clinical trials, indicate the potential clinical use of this therapeutic approach. In a clinical study, the authors showed that high doses of pHuVEGF165 improve myocardial perfusion in patients with known severe coronary artery disease and provided evidence of a dose-dependent effect [25]. However, it is important to emphasize that injection of expressive doses (500μg) may induce vascular malformation, as observed in MI rats by Schwarz et al. [26].

LV function and maximal oxygen consumption

To further investigate if the changes in LV remodeling in the pHuVEGF165 injected animals were responsible by functional positive adaptations, we evaluated the invasive and noninvasive LV function, as well as VO2 max in the experimental groups. Previous findings of our group had observed that LV dysfunction was attenuated in STZ-diabetic rats after different experimental times of MI [6,7]. In fact, in the present investigation, we evidenced better LV function evaluated invasively and noninvasively in DI+Sal in comparison with I+Sal rats. These finding suggest that experimental diabetes is associated with the activation of endogenous cardioprotective mechanisms, a better profile of calcium handling proteins [7], attenuating the remaining LV dysfunction in the DI+Sal group.

After pHuVEGF165 injection, the experimental animals had an accentuated improvement in ejection fraction, +dP/dt, -dP/dt, and LVEDP in relation to the noninjected animals, showing that the positive LV remodeling observed in these groups culminated in an attenuation of the LV dysfunction. In this sense, Giordano et al. [27] found in the cardiac VEGF-deficient mouse model a thinner LV wall and a lower LV ejection fraction compared with those in normal mice. Rottbauer et al. [28] observed that VEGF increased myocardial contractility and coronary blood flow in embryonic hearts.

Although we did not analyze the gene or protein expression of VEGF, it is possible that the delivery of VEGF was successful, since that in the present investigation LV blood flow was increased in VEGF injected animals. In this sense, we corroborated with studies in humans [29] and animals [28,30], where have been documented a stabilization or improvement in ventricular function. In addition, experimental observations also indicate that VEGF exerts a direct effect on cardiomyocyte contractility after its interaction with VEGF receptor-I and the consequent activation of PLCγ1 [28]. Taken together, these observations suggest that VEGF might have protective or regenerative functions that extend far beyond its angiogenic activity, improving global cardiac function, as observed in the present investigation.

Reduction in VO2 max has been classically reported in diabetic [31] or ischemic heart failure patients [32], and in both [33] due to cardiac and peripheral damage. In fact, Guazzi et al. [34] studying noninsulin dependent diabetic patients in New York Heart Association functional class II to III chronic heart failure, due to idiopathic or ischemic cardiac disease, observed that lung volumes and oxygen uptake were significantly more reduced compared to that in nondiabetic heart failure patients. Thus, the coexistence of diabetes seems to trigger a series of additional metabolic, functional, and hemodynamic impairments inherent to heart failure that culminate in more representative exercise intolerance. In contrast, in the present study, STZ-diabetes was not an additional condition for the impairment in VO2 max, because I+Sal and DI+Sal had similar reductions in this variable. It is possible that the experimental period utilized in our protocol was the determinant of this similarity between the groups.

Furthermore, in the present investigation, pHuVEGF165 injected animals displayed an increase in VO2 max at the end of the protocol compared with the saline injected rats. In this sense, if the classical view of VO2 assumes that this variable is limited under most circumstances by the ability of cardiovascular and respiratory systems working together to provide both a delivery system (of O2) and a removal system (of CO2) from the tissues [35], we can believe that the improvement in VO2 in I+VEGF and DI+VEGF groups is related to better ventricular function observed in these animals. Although we did not evaluate the cardiac output in the present study, it is possible that the increase in left ventricular function is associated with the improvement of this variable and, consequently, better VO2 max. In fact, Rolim et al. [36] previously showed that the reduction in VO2 response during incremental exercise in an ischemic model of heart failure is closely related to the decreased cardiac output response, largely caused by depressed stroke volume kinetics.

Study Limitations

Some possible limitations of this study deserve comments. First, in the present investigation we did not perform molecular and cellular evaluations related to the beneficial effects of pHuVEGF165 injection in the myocardium of the studied animals. However, this study provides a range of in vivo evaluations of the positive effects of VEGF gene therapy in the main parameters that are usually clinical determinants of mortality after an ischemic event. Furthermore, we measured the LV blood flow in experimental animals, providing a possible mechanism associated with the improvement of LV function and reduction of MI area in VEGF injected animals. Secondly, since the experimental rats started the protocol with similar values of MI area, left ventricular function, and VO2 max, the prediction of survival (or mortality) based on these parameters becomes difficult and is limited to methods used in this study.

Conclusions

In this animal model of diabetes and ischemic heart failure, pHuVEGF165 injected after MI surgery resulted in reduced MI area, stabilization and maintenance of left ventricular function, improvement of LV blood flow, and increased VO2 max. These positive adaptations induced considerable improvement in the survival rate.
in MI animals, diabetic or not. These results stress the importance of continuing experimental studies and controlled clinical trials of gene therapy for ischemic cardiomiopathy associated with the pathological condition of diabetes.

Acknowledgement
This study was supported by Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP-07/58942-0), Conselho Nacional de Pesquisa e Desenvolvimento (CNPq-482520/2009-4; 306011/2010-7). B.R. had a post-doctoral fellowship from CNPq. M.C.M and K.D.A. receive financial support from Conselho Nacional de Pesquisa e Desenvolvimento (CNPq-BPQ).

References
1. Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-1053.
2. Paulson DJ (1997) The diabetic heart is more sensitive to ischemic injury. Cardiovasc Res 34: 104-112.
3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229-234.
4. De Groote P, Lamblin N, Mouquet F, Plichon D, McFadden E, et al. (2004) Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart J 25: 656-662.
5. Rodrigues B, Figueroa DM, Fang J, Rosa KT, Liesy S, et al. (2011a) Short-term diabetes attenuates left ventricular dysfunction and mortality rates after myocardial infarction in rodents. Clinics (São Paulo) 66: 1437-1442.
6. Malfitano C, Alba Loureiro TC, Rodrigues B, Sirvente R, Salemi VM, et al. (2010) Hyperglycemia protects the heart after myocardial infarction: aspects of programmed cell survival and cell death. Eur J Heart Fail 12: 659-667.
7. Rodrigues B, Rosa KT, Medeiros A, Schaan BD, Brum PC, et al. (2011b) Hyperglycemia can delay left ventricular dysfunction but not autonomic damage after myocardial infarction in rodents. Cardiovasc Diabetol 10: 28.
8. Yia-Hertualia S, Aitallo K (2003) Gene transfer as a tool to induce therapeutic vascular growth. Nat Med 9: 694-701.
9. Hedman M, Hartikainen J, Syvanne M, Stjernvall J, Hedman A, et al. (2003) Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischaemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 107: 2677-2683.
10. Kukula K, Chojnowska L, Dąbrowski M, Witkowski A, Chmielak Z, et al. (2011) Intramyocardial plasmid-encoding human vascular endothelial growth factor A165/basic fibroblast growth factor therapy using percutaneous transcatheater approach in patients with refractory coronary artery disease (VIF-CAD). Am Heart J 161: 581-589.
11. Hao X, Mansson-Broberg A, Grinnemo KH, Siddiqui AJ, Delgren G, et al. (2007) Myocardial angiogenesis after plasmid or adenoviral VEGF-A(165) gene transfer in rat myocardial infarction model. Cardiovasc Res 73: 481-487.
12. Furlani AP, Kalil RA, Castro I, Cañedo-Delgado A, Barra M, et al. (2009) Effects of therapeutic angiogenesis with plasmid VEGF 165 on ventricular function in a canine model of chronic myocardial infarction. Rev Bras Cir Cardiovasc 24: 143-149.
13. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2010) Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. J Pharmacol Pharmacother 1: 94-99.
14. Jorge L, Rodrigues B, Rosa KT, Malfitano C, Loureiro TC, et al. (2011) Cardiac and peripheral adjustments induced by early exercise training intervention were associated with autonomic improvement in infarcted rats: role in functional capacity and mortality. Eur Heart J 32: 904-912.
15. Flores LJ, Figueroa D, Sanches IC, Jorge L, Irigoyen MC, et al. (2010) Effects of exercise training on autonomic dysfunction management in an experimental model of menopause and myocardial infarction. Menopause 17: 712-717.
16. Rodrigues B, Figueroa DM, Mostarda CT, Heeren MV, Irigoyen MC, et al. (2007) Maximal exercise test is a useful method for physical capacity and oxygen consumption determination in streptozotocin-diabetic rats. Cardiovasc Diabetol 6: 38.
17. Yanagisawa-Miwa A, Uchida Y, Nakamura F, Tomaru T, Kido H, et al. (1992) Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 257: 1401-1403.
18. Hariawala MD, Horowitz DF, Esakov D, Sheriff DF, Walter DH, et al. (1996) VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res 63: 77-82.
19. Goncalves LM (2000) Angiogenic growth factors: potential new treatment for acute myocardial infarction? Cardiovasc Res 45: 294-302.
20. Samuel SM, Akila V, Paul D, Thirunavukkarasu M, Zhan L, et al. (2010) CoadminISTRATION of adenoviral vascular endothelial growth factor and angiopoietin-1 enhances vascularization and reduces ventricular remodeling in the infarcted myocardium of type 1 diabetic rats. Diabetes 59: 51-60.
21. Kasuwji M, Nagamine H, Ikeda M, Sakakibara N, Takemura H, et al. (2000) Therapeutic angiogenesis with intramyocardial administration of basic fibroblast growth factor. Ann Thorac Surg 69: 1155-1161.
22. Laguens R, Cabeza Meckert P, Vera Janavel G, De Lorenzi A, Lescano E, et al. (2004) Cardiomyocyte hyperplasia after plasmid-mediated vascular endothelial growth factor gene transfer in pigs with chronic myocardial ischemia. J Gene Med 6: 222-227.
23. Kalil RA, Teixeira LA, Mastalir ET, Moreno P, Fricke CH, et al. (2002) Experimental model of gene transfection in healthy canine myocardium: perspectives of gene therapy for ischemic heart disease. Arq Bras Cardiol 79: 223-232.
24. Kastrop J, Jergensen E, Rück A, Tägli K, Glogar D, et al. (2005) Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris. A randomized double-blind placebo-controlled study: the Euroinect One trial. J Am Coll Cardiol 45: 982-988.
25. Lee LY, Patel SR, Hackett NR, Mack CA, Polce DR, et al. (2000) Focal angiogenesis therapy using intramyocardial delivery of an adenosine vector coding for vascular endothelial growth factor 121. Ann Thorac Surg 69: 14-23.
26. Schwarz ER, Speakman MT, Patterson M, Hale SS, Isner JM, et al. (2000) Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat-angiogenesis and angioma formation. J Am Coll Cardiol 35: 1323-1330.
27. Giordano FJ, Gerber HP, Williams SP, VanBruggen N, Bunting S, et al. (2001) A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci USA 98: 5780-5785.
28. Rottbauer W, Just S, Wessels G, Tranu N, Most P, et al. (2005) VEGF-PLCgamma1 pathway controls cardiac contractility in the embryonic heart. Genes Dev 19: 1624-1634.
29. Sarkar N, Rück A, Kählert G, Y-Hassan S, Blomberg P, et al. (2001) Effects of intramyocardial injection of plVEGF-A165 as sole therapy in patients with refractory coronary artery disease–12 month follow-up: angiogenic gene therapy. J Intern Med 250: 373-381.
30. Ferrarini M, Arsic N, Recchia FA, Zentlin L, Zacchigna S, et al. (2006) Adeno-associated virus-mediated transduction of VEGF165 improves cardiac tissue viability and functional recovery after permanent coronary occlusion in conscious dogs. Circ Res 98: 954-961.
31. Yki-Järvinen H, DeFranzo RA, Koivistio VA (1984) Normalization of insulin sensitivity in type I diabetic subjects by physical training during insulin pump therapy. Diabetes Care 7: 520-527.
32. Weber KT, Janicki JS, McElroy PA (1987) Determination of aerobic capacity and the severity of chronic cardiac and circulatory failure. Circulation 76: 140-145.
33. Miche G, Herrmann M, Nowak U, Wirtz M, Tietz M, et al. (2006) Effect of an exercise training program on endothelial dysfunction in diabetic and non-diabetic patients with severe chronic heart failure. Clin Res Cardiol 95: i117-i124.
34. Guazzi M, Brambilla R, Pontone G, Agostoni P, Guazzi MD (2002) Effect of non-insulin-dependent diabetes mellitus on pulmonary function and exercise tolerance in chronic congestive heart failure. Am J Cardiol 89: 191-197.
35. Saltin B, Strange S (1992) Maximal oxygen uptake: ‘old’ and ‘new’ arguments for a cardiovascular limitation. Med Sci Sports Exercise 24: 30-37.

36. Rolim NP, Mattos KC, Brum PC, Baldo MV, Middlekauff HR, et al. (2006) The decreased oxygen uptake during progressive exercise in ischemia-induced heart failure is due to reduced cardiac output rate. Braz J Med Biol Res 39: 297-304.